Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Describes Eprex Safety Findings In Petition Against Follow-On Biologics

Executive Summary

Johnson & Johnson believes that safety issues triggered by a change in stabilizers used in production of the erythropoietin Eprex support the biotechnology industry's position that "follow-on" biologics need separate clinical trials

You may also be interested in...



Thinking About Biosimilars? Meet Regulators First, Then Plan Global Development – BioAsia Conference

Opportunities in biosimilars are aplenty but regulators advise a cautious development plan to avoid late failures arising out of non-compliance.

FDA Biologic Manufacturing Comparability Policy May Apply To Follow-Ons

FDA's comparability guidance for biologics undergoing manufacturing process changes could be used to establish standards for the approval of generic biologics, according to former agency reviewers

FDA Biologic Manufacturing Comparability Policy May Apply To Follow-Ons

FDA's comparability guidance for biologics undergoing manufacturing process changes could be used to establish standards for the approval of generic biologics, according to former agency reviewers

Related Content

Topics

UsernamePublicRestriction

Register

PS044506

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel